Recent investigations in Bengaluru and Delhi have uncovered the alarming distribution of counterfeit medications in various hospitals. These incidents expose serious vulnerabilities in the pharmaceutical supply chain, revealing diverted cancer treatments originating from government hospitals. The issue encompasses more than just manufacturing flaws; it concerns the entire journey of drugs from suppliers to patients. Employing robust technology and verification processes is essential to curtail future instances of fake-drug rackets.